HUTCHMED (China) Limited (HCM)

Market Cap	2.28B -16.7%
Revenue (ttm)	548.51M -13.0%
Net Income	456.91M +1,111.0%
EPS	0.52 +1,200.0%
Shares Out	859.74M
PE Ratio	5.00
Forward PE	45.19
Dividend	n/a
Ex-Dividend Date	n/a

Volume	16,590
Open	13.22
Previous Close	13.31
Day's Range	13.17 - 13.44
52-Week Range	12.82 - 19.50
Beta	0.38
Analysts	Sell
Price Target	13.75 (+4.4%)
Earnings Date	Mar 5, 2026

About HCM

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endomet...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2000
• Employees: 1,796
• Stock Exchange: NASDAQ
• Ticker Symbol: HCM
• Website: https://www.hutch-med.com

Financial Performance

In 2025, HUTCHMED (China)'s revenue was $548.51 million, a decrease of -12.96% compared to the previous year's $630.20 million. Earnings were $456.91 million, an increase of 1111.03%.

Analyst Summary

According to one analyst, the rating for HCM stock is "Sell" and the 12-month stock price target is $13.75.

Price Target

$13.75

(4.40% upside)

Analyst Consensus: Sell